La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Transcenta Holding Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Xueming Qian

Amministratore delegato

CN¥5.6m

Compenso totale

Percentuale dello stipendio del CEO	20.3%
Mandato del CEO	12yrs
Proprietà del CEO	12.7%
Durata media del management	2.8yrs
Durata media del Consiglio di amministrazione	3.1yrs

Aggiornamenti recenti sulla gestione

Recent updates

Calculating The Intrinsic Value Of Transcenta Holding Limited (HKG:6628)

Dec 15

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Xueming Qian rispetto agli utili di Transcenta Holding?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-CN¥359m
Mar 31 2024	n/a	n/a	-CN¥411m
Dec 31 2023	CN¥6m	CN¥1m	-CN¥463m
Sep 30 2023	n/a	n/a	-CN¥451m
Jun 30 2023	n/a	n/a	-CN¥440m
Mar 31 2023	n/a	n/a	-CN¥424m
Dec 31 2022	CN¥6m	CN¥1m	-CN¥407m
Sep 30 2022	n/a	n/a	-CN¥666m
Jun 30 2022	n/a	n/a	-CN¥925m
Mar 31 2022	n/a	n/a	-CN¥2b
Dec 31 2021	CN¥5m	CN¥1m	-CN¥2b
Sep 30 2021	n/a	n/a	-CN¥1b
Jun 30 2021	n/a	n/a	-CN¥1b
Mar 31 2021	n/a	n/a	-CN¥364m
Dec 31 2020	CN¥51m	CN¥1m	-CN¥317m
Dec 31 2019	CN¥14m	CN¥823k	-CN¥395m

Compensazione vs Mercato: La retribuzione totale di Xueming ($USD 779.28K ) è superiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 235.43K ).

Compensazione vs guadagni: La retribuzione di Xueming è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Xueming Qian (55 yo)

12yrs

Mandato

CN¥5,562,000

Compensazione

Dr. Xueming Qian, Ph.D. has been Chief Executive Officer and Executive Director at Transcenta Holding Limited and serves as its Chairman since June 07, 2024. He was the Founder, Chairman and Chief Executiv...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Xueming Qian	CEO & Executive Chairman	no data	CN¥5.56m	12.66% CN¥ 68.5m
Xiaolu Weng	Executive VP & CFO	2.8yrs	CN¥8.32m	Nessun dato
Christopher Hwang	Executive VP of Process Development & CTO	5.7yrs	Nessun dato	Nessun dato
Wei Wang	VP of Investor Relations & Capital Markets Department and Secretary to the Board	2.6yrs	Nessun dato	Nessun dato
Yi Gu	Senior VP & Head of Research	5.7yrs	Nessun dato	Nessun dato
Charlie Qi	Senior Vice President of Global Clinical Development	1.7yrs	Nessun dato	Nessun dato
Xichen Zhang	Senior Vice President of Manufacturing & Quality	2.8yrs	Nessun dato	Nessun dato
Wen-I Chang	Senior Vice President of Oncology Franchise Strategy	2.5yrs	Nessun dato	Nessun dato
Caroline Germa	Executive VP of Global Medicine Development & Chief Medical Officer	2.2yrs	Nessun dato	Nessun dato
Kwan Wai Leung	Company Secretary	3.3yrs	Nessun dato	Nessun dato

2.8yrs

Durata media

52yo

Età media

Gestione esperta: Il team dirigenziale di 6628 è considerato esperto (durata media dell'incarico 2.6 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Xueming Qian	CEO & Executive Chairman	12yrs	CN¥5.56m	12.66% CN¥ 68.5m
Briggs W. Morrison	Chairman of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Pasi Antero Janne	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Kumar Srinivasan	Independent Non-Executive Director	1.8yrs	CN¥226.00k	Nessun dato
Ling Su	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Wei Chen	Independent Non-Executive Director	1.2yrs	CN¥72.00k	Nessun dato
Susan M. Jerian	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Li Xu	Member of Scientific Advisory Board	3.7yrs	Nessun dato	0.18% CN¥ 961.3k
Jiasong Tang	Independent Non-Executive Director	3.1yrs	CN¥219.00k	Nessun dato
Zhihua Zhang	Independent Non-Executive Director	3.1yrs	CN¥219.00k	Nessun dato

3.1yrs

Durata media

56yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 6628 sono considerati esperti (durata media dell'incarico 3 anni).

Transcenta Holding Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

CEO & Executive Chairman recently bought HK$64k worth of stock

CEO & Executive Chairman recently bought HK$65k worth of stock

Transcenta Holding Limited Announces the Appointment of Dr. Li Xu as A Non-Executive Director and Member of the Audit Committee

CEO & Executive Chairman recently bought HK$67k worth of stock

Transcenta Holding Limited Announces Directorate and Board Changes

Transcenta Holding Limited Announces Board and Nomination Changes

Recent updates

CEO & Executive Chairman recently bought HK$64k worth of stock

CEO & Executive Chairman recently bought HK$65k worth of stock

Transcenta Holding Limited Announces the Appointment of Dr. Li Xu as A Non-Executive Director and Member of the Audit Committee

Transcenta Holding Limited to Report First Half, 2024 Results on Aug 28, 2024

CEO & Executive Chairman recently bought HK$67k worth of stock

Transcenta Holding Limited Announces Directorate and Board Changes

Consensus EPS estimates fall by 36%

Transcenta Holding Limited Announces Updates of Phase II Data from First-Line Triple Combination Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024

Transcenta Holding Limited Announces Board and Nomination Changes

New minor risk - Market cap size

Consensus revenue estimates decrease by 17%, EPS upgraded

Transcenta Holding Limited, Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥1.14 loss per share (vs CN¥0.94 loss in FY 2022)

Transcenta Holding Limited to Report Fiscal Year 2023 Results on Mar 27, 2024

Calculating The Intrinsic Value Of Transcenta Holding Limited (HKG:6628)

CEO & Executive Director recently bought HK$74k worth of stock

Transcenta Holding Limited Announces the Publication of Preclinical Results of [177Lu]Lu-TST001 Radionuclide Antibody Conjugate as Potential Novel Treatment Option for Metastatic Gastric Cancer in the European Journal of Nuclear Medicine and Molecular Imaging

FDA Grants Transcenta Clearance to Proceed with Global Phase III Trial of Osemitamab (TST001) as First-Line Treatment for Gastric/Gastroesophageal Cancer Patients

New minor risk - Shareholder dilution

First half 2023 earnings released: CN¥0.58 loss per share (vs CN¥0.47 loss in 1H 2022)

Transcenta Holding Limited Announces Management Changes, Effective August 23, 2023

Transcenta Holding Limited to Report First Half, 2023 Results on Aug 22, 2023

Transcenta Holding Limited Receives Approval from China Center for Drug Evaluation to Initiate Phase II Clinical Trial of TST002(Blosozumab)

CEO & Executive Director recently bought HK$50k worth of stock

Transcenta Holding Limited Receives Approval from China CDE and South Korea MFDS to Initiate Transtar301 Global Phase III Pivotal Trial of Osemitamab (TST001)

CEO & Executive Director recently bought HK$70k worth of stock

Transcenta Holding Limited Announces Update on Efficacy Data of Osemitamab Plus Capecitabine and Oxaliplatin

CEO & Executive Director recently bought HK$54k worth of stock

Transcenta Holding Limited Presents Updated Data of Cohort C from Phase I/IIa, Multi-Center Study of Osemitamab

CEO & Executive Director recently bought HK$70k worth of stock

Transcenta Holding Limited Announces Encouraging Phase I Clinical Data of TST002 (Blosozumab) in Chinese Patients with Reduced Bone Mineral Density

Transcenta Holding Limited to Present Two Clinical Trial Progress At Asco 2023

Transcenta Holding Limited Announces Completion of Enrollment in COHorts C and G of China Phase II Study of Osemitamab (TST001) in Combination with Capecitabine and Oxaliplatin

CEO & Executive Director recently bought HK$72k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Transcenta Holding Limited to Present "Trial in Progress" at ASCO-GI 2023 for TST001 (Osemitamab) Combination with Nivolumab, with or without Chemotherapy in Advanced G/GEJ Cancer

Transcenta Receives IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

Transcenta Holding Limited Announces Appointment of Independent Non-Executive Director and Change in the Composition of Board Committees

High number of new and inexperienced directors

CEO & Executive Director recently bought HK$78k worth of stock

Transcenta Holding Limited Provides Update on Prevalence of Claudin18.2 and PD-L1 Expression in Chinese Gastric/Gastroesophageal Junction Adenocarcinoma

Transcenta Holding Limited Receives IND Clearance from FDA for its MASP2 Targeting Antibody TST004 for Treatment of IgA Nephropathy

CEO & Executive Director recently bought HK$72k worth of stock

Transcenta Holding Limited Receives IND Clearance from FDA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors

Transcenta Holding Limited Announces that Interim Safety and Efficacy Data of Dose Expansion Cohort from the Phase I/II Study of TST001 (Osemitamab)

Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022

First half 2022 earnings released: CN¥0.47 loss per share (vs CN¥10.19 loss in 1H 2021)

Transcenta Holding Limited to Report First Half, 2022 Results on Aug 29, 2022

Transcenta Holding Limited Announces the Appointment of Caroline Germa as Executive Vice President, Global Medicine Development and Chief Medical Officer

Transcenta Holding Limited Announces Change of the Chief Medical Officer

Transcenta Holding Limited Announces Resignation of Michael Ming Shi as Executive Director

Transcenta Holding Limited Announces That It Was Selected to Present the Preclinical Data of Tst004 At the 2022 Isn Frontiers Meetings of Complement-Related Kidney Diseases

Transcenta Holding Limited Announces Demise of Albert Da Zhu, an Executive Director and a Joint Company Secretary

Transcenta Holding Limited Publishes the Results of Preclinical Studies of the Company's First-In-Class Gremlin1 Targeting Antibody in the Treatment of Castration Resistant Prostate Cancer

Less than half of directors are independent

Transcenta Holding Limited Successfully Passes the Audit of EU Qualified Person for the Manufacturing of TST001

CEO & Executive Director recently bought HK$59k worth of stock

Transcenta Holding Limited, Annual General Meeting, Jun 10, 2022

Transcenta Announces First Patient Dosed in Phase IIa Study of Claudin18.2 Monoclonal Antibody TST001 Combined with Cisplatin and Gemcitabine for the First Line Treatment of Biliary Tract Cancer

Transcenta Holding Limited to Present Two Phase I Clinical Trials of Tst001 at Upcoming ASCO GI and IGCC

CEO & Executive Director recently bought HK$864k worth of stock

Transcenta Holding Limited Announces Business Update on the First Patient Dosed in Thephase Ib Clinical Trial of Humanized Anti-Vegfr-2Monoclonal Antibody Msb0254

Transcenta Holding Limited has completed an IPO in the amount of HKD 645.28 million.